Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of PrimeC vs Co-administered Ciprofloxacin and Celecoxib in Healthy Adults
NCT05436678Phase 1Completed
- Sponsor
- NeuroSense Therapeutics
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PrimeC in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by NeuroSense Therapeutics. Primary endpoints: Maximum Plasma Concentration (Cmax) on Day 1, Maximum Plasma Concentration (Cmax) on Day 7 and 2 more. Started Jul 2022; status: completed.
02
Drugs
PrimeC
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05436678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436678.